Ftse Mib
33.154,05
-0,10%
DAX
18.235,45
0,17%
S&P 500
5.460,48
-0,41%
NASDAQ
17.732,60
-0,71%
Bitcoin
61.022,11
1,18%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Vicuron Pharmaceuticals (MM) (MICU) Vicuron Pharmaceuticals (MM) (MICU) Notizie

MICU

Vicuron (MICU)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MICU
DataOraFonteTitoloSimboloCompagnia
14/09/200510:00PR Newswire (US)Pfizer Completes Acquisition of Vicuron PharmaceuticalsNASDAQ:MICU
11/09/200519:00PR Newswire (US)Vicuron Pharmaceuticals - Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Expected Closing Date for AcquisitionNASDAQ:MICU
18/08/200523:30PR Newswire (US)Vicuron Pharmaceuticals Files New Drug Application (NDA) for Anidulafungin for Treatment of Invasive Candidiasis/CandidemiaNASDAQ:MICU
15/08/200523:30PR Newswire (US)Vicuron Pharmaceuticals Stockholders Approve Merger With PfizerNASDAQ:MICU
04/08/200523:30PR Newswire (US)Vicuron Pharmaceuticals Announces Second Quarter 2005 Financial ResultsNASDAQ:MICUVicuron Pharmaceuticals (MM)
16/06/200508:00PR Newswire (US)Pfizer to Acquire Vicuron Pharmaceuticals to Extend its Research Commitment in Anti-InfectivesNASDAQ:MICUVicuron Pharmaceuticals (MM)
02/06/200509:00PR Newswire (US)Vicuron Pharmaceuticals Receives Issued Patent for Dalbavancin Dosing by U.S. Patent and Trademark OfficeNASDAQ:MICU
31/05/200509:00PR Newswire (US)Vicuron Pharmaceuticals Files Amendment to Anidulafungin New Drug Application (NDA) for Treatment of Esophageal CandidiasisNASDAQ:MICU
26/05/200523:30PR Newswire (US)Vicuron Pharmaceuticals to Present at the Friedman Billings Ramsey 9th Annual Growth Investor Conference and the Pacific GrowthNASDAQ:MICU
17/05/200523:30PR Newswire (US)Vicuron Pharmaceuticals to Present at the 2005 Needham Biotech ConferenceNASDAQ:MICU
11/05/200509:00PR Newswire (US)Vicuron Pharmaceuticals Announces Extension of FDA Review of Dalbavancin New Drug ApplicationNASDAQ:MICU
09/05/200523:30PR Newswire (US)Vicuron Pharmaceuticals to Present at the Bear Stearns 2005 Healthcare Conference and the Banc of America Securities HealthcareNASDAQ:MICU
05/05/200523:30PR Newswire (US)Vicuron Pharmaceuticals Announces First Quarter 2005 Financial ResultsNASDAQ:MICU
28/04/200514:30PR Newswire (US)Vicuron Pharmaceuticals to Present at Morgan Stanley Healthcare Unplugged ConferenceNASDAQ:MICU
31/03/200500:30PR Newswire (US)Vicuron Pharmaceuticals Extends Pfizer Deal to Develop Oral Antibiotics for Community MarketNASDAQ:MICU
10/03/200522:30PR Newswire (US)Vicuron Pharmaceuticals Announces Fourth Quarter 2004 Financial ResultsNASDAQ:MICU
10/03/200513:30PR Newswire (US)Vicuron Pharmaceuticals to Present at the SG Cowen & Co. 25th Annual Health Care ConferenceNASDAQ:MICU
04/03/200508:00PR Newswire (US)Vicuron Pharmaceuticals Provides Update on Novartis Peptide Deformylase Inhibitor ProgramNASDAQ:MICU
25/02/200513:30PR Newswire (US)Vicuron Pharmaceuticals to Present at the Wells Fargo Securities Healthcare ConferenceNASDAQ:MICU
24/02/200508:00PR Newswire (US)Vicuron Pharmaceuticals Granted Priority Review of Dalbavancin NDA by FDA in Complicated Skin and Soft Tissue InfectionsNASDAQ:MICU
17/02/200513:30PR Newswire (US)Vicuron Pharmaceuticals to Present at the BIO CEO & Investor Conference 2005NASDAQ:MICU
07/02/200508:00PR Newswire (US)Vicuron Pharmaceuticals Announces Phase 3 Trial Results Demonstrate Superiority of Anidulafungin Versus Fluconazole in InvasiveNASDAQ:MICU
24/01/200508:00PR Newswire (US)Vicuron Pharmaceuticals Promotes David S. Krause, M.D., to Executive Vice President and Chief Medical OfficerNASDAQ:MICU
05/01/200513:30PR Newswire (US)Vicuron Pharmaceuticals to Present at the 23rd Annual JP Morgan Healthcare ConferenceNASDAQ:MICU
21/12/200422:30PR Newswire (US)Vicuron Pharmaceuticals Submits New Drug Application for Dalbavancin to U.S. Food and Drug AdministrationNASDAQ:MICU
29/11/200413:30PR Newswire (US)Vicuron Pharmaceuticals to Present at the Lazard Freres & Co. Healthcare ConferenceNASDAQ:MICU
04/11/200422:30PR Newswire (US)Vicuron Pharmaceuticals Announces Third Quarter 2004 Financial ResultsNASDAQ:MICU
01/11/200408:00PR Newswire (US)Vicuron Pharmaceuticals Announces Data at ICAAC Supporting Next-Generation Lincosamide ProgramNASDAQ:MICU
01/11/200408:00PR Newswire (US)Vicuron Pharmaceuticals Announces Data at ICAAC Demonstrating Potency of Anidulafungin and DalbavancinNASDAQ:MICU
25/10/200414:30PR Newswire (US)Vicuron Pharmaceuticals Announces 40 Presentations at ICAAC Highlighting Pipeline and Late-Stage ProductsNASDAQ:MICU
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MICU

La tua Cronologia

BIT
UB4Q6R
Unicredit Bank
BIT
P21JN3
NLBNPIT21JN3 20241218 2500
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network